Pfizer expands venture arm with $600m cash boost
NICE has issued a Final Appraisal Determination that recommends the use of Pfizer’s Xalkori (crizotinib) in England under the Cancer Drugs Fund (CDF) for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).
Pfizer’s janus kinase (JAK) inhibitor drug Xeljanz (tofacitinib) has received expanded approval from the FDA for adults with moderately-to-severely-active ulcerative colitis.
NICE blocks access to 65% of patients on cost grounds
Epoetin alfa biosimilars available in EU for more than a decade
CEO says investment will focus on pipeline